Prevalence and risk factors of hepatitis B virus reactivation in patients with solid tumors with resolved HBV infection.
HBs antibody
de novo hepatitis
resolved HBV infection
solid tumor
steroid
Journal
Asia-Pacific journal of clinical oncology
ISSN: 1743-7563
Titre abrégé: Asia Pac J Clin Oncol
Pays: Australia
ID NLM: 101241430
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
received:
30
11
2017
accepted:
18
06
2018
pubmed:
10
7
2018
medline:
7
3
2019
entrez:
10
7
2018
Statut:
ppublish
Résumé
Reports of hepatitis B virus (HBV) reactivation in solid tumors are very limited, and their frequencies and risk factors were previously unknown. To evaluate the prevalence and risk factors of HBV reactivation in patients with solid tumors with resolved HBV infection. All 1088 patients with solid tumors were assessed for eligibility; 251 patients had resolved HBV infection (negative for HBs antigen and positive for anti-HBc antibody and/or positive for anti-HBs antibody), and HBV-DNA was assessed for 243 of these patients in whom we analyzed the prevalence of HBV reactivation. Risk factors for HBV reactivation were exploratorily evaluated by analysis of a case-control study. The prevalence of HBV-DNA reactivation was 2.1% (95% confidence interval [CI], 0.3-3.9%). We did not observe any exacerbation of HBV-DNA by early intervention. A low anti-HBs antibody titer (<10.0 mIU/mL) and high average daily dexamethasone dose (>1.0 mg/day) were high risk factors, with odds ratios of 5.94 (95% CI, 1.15-30.6, P = 0.03) and 8.69 (95% CI, 1.27-58.8, P = 0.02), respectively. HBV reactivation in solid tumor patients was relatively rare. Therefore, risk factors that can identify targets for HBV screening must be determined in future studies.
Sections du résumé
BACKGROUND
BACKGROUND
Reports of hepatitis B virus (HBV) reactivation in solid tumors are very limited, and their frequencies and risk factors were previously unknown.
AIM
OBJECTIVE
To evaluate the prevalence and risk factors of HBV reactivation in patients with solid tumors with resolved HBV infection.
METHODS
METHODS
All 1088 patients with solid tumors were assessed for eligibility; 251 patients had resolved HBV infection (negative for HBs antigen and positive for anti-HBc antibody and/or positive for anti-HBs antibody), and HBV-DNA was assessed for 243 of these patients in whom we analyzed the prevalence of HBV reactivation. Risk factors for HBV reactivation were exploratorily evaluated by analysis of a case-control study.
RESULTS
RESULTS
The prevalence of HBV-DNA reactivation was 2.1% (95% confidence interval [CI], 0.3-3.9%). We did not observe any exacerbation of HBV-DNA by early intervention. A low anti-HBs antibody titer (<10.0 mIU/mL) and high average daily dexamethasone dose (>1.0 mg/day) were high risk factors, with odds ratios of 5.94 (95% CI, 1.15-30.6, P = 0.03) and 8.69 (95% CI, 1.27-58.8, P = 0.02), respectively.
CONCLUSION
CONCLUSIONS
HBV reactivation in solid tumor patients was relatively rare. Therefore, risk factors that can identify targets for HBV screening must be determined in future studies.
Identifiants
pubmed: 29984542
doi: 10.1111/ajco.13050
pmc: PMC7379615
doi:
Substances chimiques
Antiviral Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
63-68Informations de copyright
© 2018 The Authors. Asia-Pacific Journal of Clinical Oncology Published by John Wiley & Sons Australia, Ltd.
Références
Proc Natl Acad Sci U S A. 1986 Mar;83(6):1627-31
pubmed: 3006059
Ann Rheum Dis. 2017 Jun;76(6):1051-1056
pubmed: 27934678
Hepatol Res. 2012 Jul;42(7):627-36
pubmed: 22686858
Ann Oncol. 2016 Sep;27(suppl 5):v119-v133
pubmed: 27664248
J Clin Oncol. 2009 Feb 1;27(4):605-11
pubmed: 19075267
Clin Infect Dis. 2008 Sep 1;47(5):e52-6
pubmed: 18643758
Intervirology. 2004;47(1):32-40
pubmed: 15044834
Hepatology. 2017 Aug;66(2):379-388
pubmed: 28128861
Clin Infect Dis. 2015 Sep 1;61(5):719-29
pubmed: 25935551
J Clin Oncol. 2016 Feb 1;34(4):381-6
pubmed: 26527784
Int J Clin Oncol. 2016 Feb;21(1):1-12
pubmed: 26081252
Ann Oncol. 2016 Dec;27(12):2172-2184
pubmed: 27803003
Curr Oncol. 2010 Nov;17(6):32-8
pubmed: 21151407
Saudi J Gastroenterol. 2012 Jul-Aug;18(4):277-81
pubmed: 22824772
Int J Clin Oncol. 2016 Dec;21(6):1162-1166
pubmed: 27260010
J Clin Virol. 2007 Jan;38(1):83-6
pubmed: 17134939
Asia Pac J Clin Oncol. 2019 Feb;15(1):63-68
pubmed: 29984542
World J Gastroenterol. 2013 Feb 14;19(6):923-30
pubmed: 23429298
Hepatology. 1992 Jul;16(1):13-8
pubmed: 1319949
J Hepatol. 2012 Jul;57(1):167-85
pubmed: 22436845
J Clin Oncol. 2011 Aug 20;29(24):3270-7
pubmed: 21788556